Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Disease symptoms in AAV vary by age at diagnosis, sex, study finds

Disease symptoms among people with ANCA-associated vasculitis (AAV) were found to vary by age at diagnosis and biological sex, according to data from more than 1,100 Scandinavian patients. “We identified significant differences in clinical presentation of the disease between female and male patients and between patients with a young…

Remission rate, treatment response varies by AAV type: Study

The likelihood of disease recurrence in people with anti-neutrophilic cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) varies by disease type, with those with granulomatosis with polyangiitis (GPA) more likely to see their disease come back following successful treatment than people with microscopic polyangiitis (MPA), a study found. Patients with MPA may be…

Lixudebart shows good safety in trial of AAV with kidney damage

Lixudebart (ALE.F02), an experimental therapy Alentis Therapeutics is developing to help preserve kidney health in ANCA-associated vasculitis (AAV), showed a favorable safety profile in a Phase 2 clinical trial, the company has announced. A separate study testing lixudebart in people with liver disease also showed a good safety…

ADX-097, potential AAV therapy, fares well in healthy volunteers

ADX-097, an experimental tissue-targeted therapy that Q32 Bio is developing for ANCA-associated vasculitis (AAV) and other diseases marked by overactivity of the immune complement system, was well tolerated in a Phase 1 clinical trial involving healthy volunteers. The study’s data also indicated that ADX-097 showed a favorable pharmacological…

ANCA blood tests may help detect kidney involvement: Study

Blood tests that look for the anti-neutrophil cytoplasmic autoantibodies (ANCAs) that cause ANCA-associated vasculitis (AAV) may help identify patients with kidney involvement, a study shows. Still, ANCA testing was not as accurate for this purpose as a kidney biopsy, wherein a small piece of kidney tissue is collected…

New B-cell growth is impaired in AAV, study finds

The production of new B-cells, a type of immune cell that helps fight infections but is also involved in the abnormal immune attacks that drive ANCA-associated vasculitis (AAV), is dysfunctional in people with the autoimmune disease, a study found. The findings could help shed light on the biological underpinnings…

EGPA disease symptoms don’t vary with ANCA status, study finds

Symptoms and disease manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), a rare type of ANCA-associated vasculitis (AAV), are generally similar between patients with and without ANCAs, the self-reactive antibodies that drive most AAV cases. That’s according to a study analyzing data from a registry of people with vasculitis, or…

Rituximab cuts recurrence risk in subglottic stenosis surgery: Study

Rituximab is superior to other immunosuppressive treatments at preventing post-surgery relapse in granulomatosis with polyangiitis (GPA) patients undergoing surgery to address subglottic stenosis, a common complication that causes airway narrowing. That’s according to a study that analyzed data from 25 GPA patients who were followed for more than…

EGPA, kidney damage raise risk of blood clots in AAV patients: Study

People with the rarest type of ANCA-associated vasculitis (AAV), called eosinophilic granulomatosis with polyangiitis (EGPA), and AAV patients with reduced kidney function are more likely to experience thrombosis (blood clots that disrupt blood flow), according to a single-center study in China. Results also indicated AAV patients with higher…